Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. - Wikidata - awgldk - TriplyDB

Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo.

Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo.

http://www.wikidata.org/entity/Q34514599

about

Prevention of Alzheimer's disease Statins for the treatment of dementia Statins for the treatment of dementia Statins for the prevention of dementia Mutations in the 3beta-hydroxysterol Delta24-reductase gene cause desmosterolosis, an autosomal recessive disorder of cholesterol biosynthesis The cholesterol transporter ABCG1 modulates the subcellular distribution and proteolytic processing of beta-amyloid precursor protein Apolipoprotein E (ApoE) isoform-dependent lipid release from astrocytes prepared from human ApoE3 and ApoE4 knock-in mice The role of seladin-1/DHCR24 in cholesterol biosynthesis, APP processing and Abeta generation in vivo.ABCA1 and scavenger receptor class B, type I, are modulators of reverse sterol transport at an in vitro blood-brain barrier constituted of porcine brain capillary endothelial cells Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE)RXRA gene variations influence Alzheimer's disease risk and cholesterol metabolism Pathways towards and away from Alzheimer's disease Novel therapeutics for Alzheimer's disease: an update Pleiotropic effects of statins Lipoprotein receptors and cholesterol in APP trafficking and proteolytic processing, implications for Alzheimer's disease Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts Modulation of statin-activated shedding of Alzheimer APP ectodomain by ROCK Linking lipids, Alzheimer's and LXRs?Unfolded Protein Response and Macroautophagy in Alzheimer's, Parkinson's and Prion Diseases The roles of lipid and glucose metabolism in modulation of β-amyloid, tau, and neurodegeneration in the pathogenesis of Alzheimer disease Alzheimer's disease and insulin resistance: translating basic science into clinical applications Cholesterol balance in prion diseases and Alzheimer's disease A novel therapeutic effect of statins on nephrogenic diabetes insipidus Roles of vascular and metabolic components in cognitive dysfunction of Alzheimer disease: short- and long-term modification by non-genetic risk factors Oxidized cholesterol as the driving force behind the development of Alzheimer's disease Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials.The Guinea Pig as a Model for Sporadic Alzheimer's Disease (AD): The Impact of Cholesterol Intake on Expression of AD-Related Genes Differential contributions of ApoE4 and female sex to BACE1 activity and expression mediate Aβ deposition and learning and memory in mouse models of Alzheimer's disease Cyclodextrins as Emerging Therapeutic Tools in the Treatment of Cholesterol-Associated Vascular and Neurodegenerative Diseases The Impact of Vitamin E and Other Fat-Soluble Vitamins on Alzheimer´s Disease ACAT1/SOAT1 as a therapeutic target for Alzheimer's disease Ceramides in Alzheimer's Disease: Key Mediators of Neuronal Apoptosis Induced by Oxidative Stress and Aβ Accumulation Genetic association of acyl-coenzyme A: cholesterol acyltransferase with cerebrospinal fluid cholesterol levels, brain amyloid load, and risk for Alzheimer's disease Polymorphism in the cholesterol 24S-hydroxylase gene is associated with Alzheimer's disease Ongoing clinical trials of the pleiotropic effects of statins Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy Cysteine protease inhibitors reduce brain beta-amyloid and beta-secretase activity in vivo and are potential Alzheimer's disease therapeutics SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis Dynamics and Cleavability at the alpha-cleavage site of APP(684-726) in different lipid environments Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases

P2860

Q22248031-61F91789-FB90-48B2-AD6A-9F8515530859 Q24194901-E9DD721C-8A1D-4448-A2DC-45C2FD817F1E Q24236484-8B6CF6D2-53C2-4261-91BA-0DD0AC8633C3 Q24241335-0146F785-3002-4CDB-9EFA-B6AF3B865F59 Q24291608-07EC547B-B6A7-4772-BEFE-A9945623C456 Q24296758-F885DED5-4F6F-4ED7-AE0C-A606D99A6B14 Q24298652-D2B0F2BD-6525-4E54-BE25-69A936A34754 Q24300901-D216666A-5D81-4D11-A9BB-02B522A2878C Q24305511-2037DDFA-C14E-4EE9-B07D-5AC02E16D607 Q24306455-D4FD615B-4ABE-4747-B0C4-642B976D60DD Q24317054-4CC77C0D-A50D-47D2-BAD3-FDE7A14C60A1 Q24596270-CBFEAAFB-AAB2-48A0-A1D4-721A90374510 Q24620383-07AB77AC-9687-4ED0-B6F0-2E4555CE565E Q24647863-9D33B66B-1DC7-465F-89D7-D378D84D3DD9 Q24650450-6858E385-CF06-439E-8C25-6B21DC0BA90A Q24675729-4B6EC98B-1AEA-4EC5-8230-E55757CADE30 Q24798788-7CB50773-636B-4DEB-AA31-CC9663E4D45A Q25255165-07622B4B-E9D9-4281-92B0-29C06A7DEFEC Q26773443-C8EF6A2B-F807-4860-9FEA-7CADB556349C Q26777969-5F4F509A-2E58-4693-BA43-9CE78AACB3F4 Q26996487-C6E686AF-B705-407A-A5DE-533CFE9F28F4 Q27002948-EC63F1DC-4EF0-40D9-8688-931C3E10B204 Q27005638-84F30450-998F-4ADB-9CD7-6C43E1A3ED79 Q27022694-9978A6CC-E074-4E14-92E7-B29064CAD3C4 Q27023315-AD00CF37-A265-478B-B806-1968EB43BE4E Q27310276-74CD21F1-BBE4-44E8-8D52-3CD9DD0381A6 Q27315066-44FB18AF-58C3-4C7E-A14D-6BB9B86F01A6 Q27323892-6A89442F-057D-417B-97F4-B4AFD3FBA1BE Q28071254-EC24BABF-0FFF-40AC-927A-BFF9AB59FF3C Q28074531-4EC5386C-7635-4557-B47C-D645757DDF6E Q28081654-528F670B-F60E-4F74-AF7C-C40C19843ABF Q28087030-ECD8CE2D-110A-4F00-8779-31D88FCCF85C Q28186052-175AC41B-DEAF-4F8B-BB57-86836DA5838C Q28201917-081360B2-F763-4D2B-90D1-1907DD91C99A Q28219321-E6BFDCB2-8CAF-4FE8-B9A2-ABA4191A6B72 Q28235507-0CA8BDD6-971F-4E43-8064-5F27A0B2A0A3 Q28240590-3C08DAC4-F46D-4A72-B056-FB9904001026 Q28279273-F1536F16-4EDF-487F-887A-B0B1B4922C68 Q28384987-860B1747-0925-443A-8403-83F02065E14C Q28388335-18E8DE97-2443-4378-9E4C-87509998AD86

P2860

Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo.

http://www.wikidata.org/entity/Q34514599

description

2001 nî lūn-bûn

@nan

2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Simvastatin strongly reduces l ...... Abeta 40 in vitro and in vivo.

@ast

Simvastatin strongly reduces l ...... Abeta 40 in vitro and in vivo.

@en

Simvastatin strongly reduces l ...... Abeta 40 in vitro and in vivo.

@nl

type

label

Simvastatin strongly reduces l ...... Abeta 40 in vitro and in vivo.

@ast

Simvastatin strongly reduces l ...... Abeta 40 in vitro and in vivo.

@en

Simvastatin strongly reduces l ...... Abeta 40 in vitro and in vivo.

@nl

prefLabel

Simvastatin strongly reduces l ...... Abeta 40 in vitro and in vivo.

@ast

Simvastatin strongly reduces l ...... Abeta 40 in vitro and in vivo.

@en

Simvastatin strongly reduces l ...... Abeta 40 in vitro and in vivo.

@nl

P1433

Q34514599-852ADA8F-72C3-43C8-82AC-29A416F7FF7F

P1476

Q34514599-A8186625-9B1E-4366-94EF-44916BF36B1B

P2093

Q34514599-15339F27-0A7C-4C15-9453-BA3EB1A89EB2

Q34514599-154FE4FA-E400-44AA-93DB-90ADBE8D5EAF

Q34514599-2BB291E2-D4DB-4E8E-8F31-DA47E876DD32

Q34514599-3CAAFB71-B6ED-4B92-8BBB-1924ED21A2AB

Q34514599-57A80FE7-8A0C-4C4A-910D-93C84DA06AB0

Q34514599-9BA8B388-5FDE-437F-9704-63FE2945EB78

Q34514599-B7F98BDF-756A-4F67-911F-A1E05A2DE6B7

Q34514599-BC49359B-4BEA-4263-9C90-BB9C3DF264BC

Q34514599-C909428A-4D52-4A04-919A-530F8A85DBE6

Q34514599-CAE44FC5-6236-410E-9F9F-31EEA3183610

P2860

Q34514599-0A6A91D4-47DB-44AF-8B67-60ADE3F38737

Q34514599-0EFE52E7-1905-4D17-BE27-C4D40EF557CE

Q34514599-14FB46F9-8602-4145-8329-5354E113C2D0

Q34514599-1674E3CD-64DD-4210-9DF9-53C70545ADDA

Q34514599-1747EBD7-477F-48CD-B4CF-AC65649A8EE4

Q34514599-1BFB0CF5-19A9-4833-9A8E-0D145363A04F

Q34514599-21560881-3F7A-458B-9D45-7768E83891AA

Q34514599-283B4013-8EC5-42ED-B6A9-0DA6BC3FCDC9

Q34514599-2A1A658D-EBE6-4647-94E2-573FBDC147F4

Q34514599-35CBF8AE-78D4-46D4-99E2-66368FF7C4DA

P304

Q34514599-B90ACFE8-864C-4E17-A9CF-ACBB6A6B9289

P31

Q34514599-E6B1D844-7D87-4E5D-8C0A-C1C134A630C1

P356

Q34514599-89BD4796-36DA-4629-AEC3-493F3C738BA8

P407

Q34514599-867BFE69-1258-4B3B-B14F-54D3534B9BDC

P433

Q34514599-7CDDC0C3-E942-4612-9C53-B61DF1105A3C

P478

Q34514599-9F9F351D-97B0-4F38-9E46-5288C50B9B8C

P50

Q34514599-43B72F15-5650-4158-ADC8-4181897EBB8B

P577

Q34514599-EE775FEA-5DE0-4413-8305-EE3E655741EE

P5875

Q34514599-9C08419F-7284-4A51-BAE9-7D933245D780

P698

Q34514599-880B8140-97FE-463A-A823-67D88C1A8B87

P921

Q34514599-D9CD13A9-6684-4778-9D6F-A24BC187106B

P932

Q34514599-096A4690-8C50-4415-900D-81237D5D29E8

P356

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Simvastatin strongly reduces l ...... Abeta 40 in vitro and in vivo.

@en

P2093

C Bergmann

http://www.w3.org/2001/XMLSchema#string

D Lutjohann

http://www.w3.org/2001/XMLSchema#string

H Runz

http://www.w3.org/2001/XMLSchema#string

K Beyreuther

http://www.w3.org/2001/XMLSchema#string

K Fassbender

http://www.w3.org/2001/XMLSchema#string

K von Bergmann

http://www.w3.org/2001/XMLSchema#string

M Hennerici

http://www.w3.org/2001/XMLSchema#string

M Simons

http://www.w3.org/2001/XMLSchema#string

M Stroick

http://www.w3.org/2001/XMLSchema#string

P Keller

http://www.w3.org/2001/XMLSchema#string

P2860

Presenilin 1 is linked with gamma-secretase activity in the detergent solubilized state

A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood

Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase

A simple method for the isolation and purification of total lipides from animal tissues

Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families

Functional rafts in cell membranes

Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease

The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor

P304

5856-5861

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.081620098

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

98

http://www.w3.org/2001/XMLSchema#string

P50

Tobias Hartmann

P577

2001-04-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12038351

http://www.w3.org/2001/XMLSchema#string

P698

11296263

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

33303

http://www.w3.org/2001/XMLSchema#string